Skip to content

Comparison of efficacy and safety between high-dose amoxicillin-vonoprazan dual therapy and quadruple therapy with bismuth and furazolidone for Helicobacter pylori remedial eradication

Comparison of efficacy and safety between high-dose amoxicillin-vonoprazan dual therapy and quadruple therapy with bismuth and furazolidone for Helicobacter pylori remedial eradication

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052604
Enrollment
Unknown
Registered
2021-11-02
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

experimental group :high-dose amoxicillin-vonoprazan dual therapy

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years; 2. 13C urea breath test is positive; 3. Meet the indications for Helicobacter pylori eradication (according to the Fifth National Consensus Report on the Treatment of Helicobacter pylori Infection); 4. Patients who have failed to take the quadruple regimen for 10-14 days at least twice in the past and need to undergo gastroscopy; 5. Those who have received Helicobacter pylori eradication therapy in the past need to stop the drug for more than 3 months before entering the group.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to the drugs used in the eradication program; 2. Patients with a history of ß-lactam allergy, allergic constitution and allergic reaction. 3. After gastric surgery; 4. Pregnant and lactating women; 5. Taking glucocorticoids, non-steroidal drugs, anticoagulants; 6. Patients with low body weight (weight less than 40kg), patients with severe liver, kidney, cardiac insufficiency, malignant tumor, and cerebrovascular disease.

Design outcomes

Primary

MeasureTime frame
13C urea breath test;

Countries

China

Contacts

Public ContactWang Weihong

Peking University First Hospital

wangweihong2581@163.com+86 13041171610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026